Back to Authors

Carrillo‐Martin, Ismael

A5004136039 | I4210146710

Mayo Clinic

Mayo Clinic in Florida

Citations 6

State-of-the-art beta-adrenoreceptor agonists for the treatment of asthma

Expert Opinion on Pharmacotherapy | November 10, 2021 | Volume: 23 | Issue: 2 | Pages: 243-254

10.1080/14656566.2021.1988074 | PMID 34753370

Chemotherapy‐induced anaphylaxis and fatal anaphylaxis in the United States: Incidence and risk factors

Clinical & Experimental Allergy | September 4, 2021 | Volume: 51 | Issue: 11 | Pages: 1514-1518

10.1111/cea.14011 | PMID 34480372

Self-injectable epinephrine: doctors’ attitude and patients’ adherence in real-life

Current Opinion in Allergy & Clinical Immunology | July 13, 2020 | Volume: 20 | Issue: 5 | Pages: 474-481

10.1097/aci.0000000000000664 | PMID 32657793

Purpose of review Epinephrine is the only life-saving treatment of anaphylaxis. Prescription and administration rates of self-injectable epinephrine are generally low. It is unclear whether this is because of availability, low prescription rates, fear of using epinephrine, or a combination of these issues. Recent findings This review focuses on what self-injectable epinephrine devices (SIED), such as auto-injectors and prefilled syringes, are preferred by patients and healthcare professionals (HCP). Our findings suggest that a device's ease to use, proper and frequent training on its operability, and availability have an impact on preferences and adherence to treatment with SIEDs. After prescribing a patient with a SIED, clinicians should emphasize its use in anaphylaxis, educate patients/caregivers to identify anaphylaxis and on how to use the SIED, and encourage constant practicing with training devices. Summary Epinephrine is the sole recommended anaphylaxis treatment and SIEDs are of critical usefulness in the community setting. Further studying of these devices is needed to optimize education for HCPs and patients and their accessibility to SIEDs.
Documented exogenous progesterone hypersensitivity related to the use of combined oral contraceptive

BMJ Case Reports | September 9, 2019 | Volume: 12 | Issue: 9 | Pages: e230416

10.1136/bcr-2019-230416 | PMID 31501174

MON-598 Self-Reported Allergy to Thyroid Replacement Therapy: A Retrospective Chart Review

Journal of the Endocrine Society | May 10, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: No page available

10.1210/js.2019-mon-598

Bepotastine besilate for the treatment of perennial allergic rhinitis

Expert Opinion on Pharmacotherapy | September 12, 2018 | Volume: 19 | Issue: 15 | Pages: 1727-1730

10.1080/14656566.2018.1519020 | PMID 30208284